Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06282159 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
A Phase 2 study of Myasthenia Gravis, Generalized, sponsored by Dianthus Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
- 20
- Study locations
NCT06282159: Active Phase 2 study of Myasthenia Gravis, Generalized, sponsored by Dianthus Therapeutics.
NCT06282159 is a Phase 2 study of Myasthenia Gravis, Generalized that is active but no longer recruiting, run by Dianthus Therapeutics. The registered enrollment target is 65 participants, below the 1,316-participant average among 3 other Myasthenia Gravis, Generalized trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06282159, a Phase 2 study of Myasthenia Gravis, Generalized, is active but no longer recruiting, sponsored by Dianthus Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG).
Primary Outcome
Number of participants with TEAEs and treatment-emergent SAEs will be reported.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG DNTH103
Study Locations (20)
Texas
- Clinical Study Site - Dallas
- Clinical Study Site - Dallas
- Clinical Study Site #2 - Houston
- Clinical Study Site - Houston
- Clinical Study Site - Lubbock
Florida
- Clinical Study Site - Boca Raton
- Clinical Study Site - Bradenton
- Clinical Study Site - Maitland
- Clincal Study Site - Tampa
Ohio
- Clinical Study Site - Cincinnati
- Clinical Study Site - Columbus
Arizona
- Clinical Study Site - Phoenix
California
- Clinical Study Site - Irvine
Connecticut
- Clinical Study Site - Stamford
Illinois
- Clinical Study Site - O'Fallon
Kansas
- Clinical Study Site - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2024-02-23 |
| Est. Completion | 2027-08 |
| Phase | Phase 2 |
What the registry record for NCT06282159 still lists
NCT06282159 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 1,316-participant average among 3 other Myasthenia Gravis, Generalized trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Myasthenia Gravis, Generalized appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06282159 names 20 study sites across 12 states, led by Texas, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT06282159 about?
NCT06282159 is a clinical study titled "A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)". The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG).
What is the current status of trial NCT06282159?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2024-02-23. Estimated completion is 2027-08.
What conditions does trial NCT06282159 study?
This clinical trial studies the following conditions: Myasthenia Gravis, Generalized.
What interventions are being tested in trial NCT06282159?
The interventions under investigation include: Placebo (DRUG), DNTH103 (DRUG).
Who is sponsoring clinical trial NCT06282159?
This trial is sponsored by Dianthus Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06282159 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenia Gravis, Generalized
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
ACTIVE NOT RECRUITING · Phase 2
-
Myasthenia Gravis Foundation of America Global MG Patient Registry
RECRUITING
-
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI